A Randomized Multicenter, Double-Blind, Placebo-Controlled Comparison of Chemotherapy Plus Trastuzumab Plus Placebo Versus Chemotherapy Plus Trastuzumab Plus Pertuzumab as Adjuvant Therapy in Patients With Operable HER2-Positive Primary Breast Cancer
收藏DataCite Commons2026-03-03 更新2024-07-13 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00006469/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
This randomized, double-blind, placebo-controlled, two-arm study will assess the safety and
efficacy of pertuzumab in addition to chemotherapy plus trastuzumab as adjuvant therapy in
participants with operable HER2-positive primary breast cancer. This study will be carried
out in collaboration with the Breast International Group (BIG).
提供机构：
Vivli
创建时间：
2020-11-05
